ArticleInfluenza and other respiratory viruses2025
Seasonal Influenza Vaccine 2021/2022 Provides Limited Cross Reactivity Against Contemporary Swine Influenza A Virus Strains in Spain.
Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Zoonotic infections and genomic evolution of novel reassortant swine influenza A viruses in Spain.bioRxiv : the preprint server for biology · 2026Article
- Seasonal Influenza Vaccine 2021/2022 Provides Limited Cross Reactivity Against Contemporary Swine Influenza A Virus Strains in Spain.Influenza and other respiratory viruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Swine influenza A viruses (SIVs) pose a zoonotic risk, with variants detected in humans in Europe. This study evaluated the efficacy of the 2021/2022 seasonal influenza vaccine against SIVs. Forty-six postvaccination human sera were tested via hemagglutination inhibition (HI) assay against Spanish SIV genotypes. Seroprotection rate (SPR, HI titer ≥ 40) was 76% (95% CI: 64-88) and 91% (95% CI: 83-99) for human vaccine strains H1 and H3, respectively. SPRs were 67% (95% CI: 53-81) for pandemic swine H1, 64% (95% CI: 50-78) for human seasonal-like H1, 17%-46% for Eurasian avian-like H1, 15% (95% CI: 5-25) for human seasonal-like H3 from the 1970s, and 83%-93% for human seasonal-like H3 from the 2000s SIVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.